Ahmedzai SH, et al. - Given that for patients with multiple myeloma (MM) relapsing after a prior autologous stem-cell transplantation, salvage autologous stem-cell transplantation (sASCT) increases remission duration and overall survival, researchers sought to report on patient-reported outcomes, including quality of life (QoL) and pain in sASCT. They randomly assigned patients to either sASCT or nontransplantation consolidation. They noted a relative reduction in QoL and larger impact of treatment adverse effects lasting for 6 months and up to 2 years for pain among patients with sASCT for relapsed MM. After this, better outcomes were reported for patients who had received sASCT. Longer time to progression and overall survival were evident in patients who experienced lower adverse effects after sASCT, indicating the necessity of improving symptom management peritransplantation. In patients with relapsed MM, this study seems to offer the most comprehensive picture of QoL before and after sASCT.